hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Symptoms === Pain Paresthesia Spasticity, Hypertonia Muscular Dysfunction or Weakness Radiculopathy Although Tarlov Cysts can develop anywhere along the spine, they are most commonly symptomatic in the sacrum. Women are more likely to exhibit symptoms. They can also appear in clusters or bilaterally along the spine, thus symptoms can be unilateral, bilateral, or with symptoms more dominant on one side. The cases of reported symptomatic Tarlov cysts ranges from 15% to 30% of the overall reported Tarlov cyst cases, depending on the source of literature. Nevertheless, these cysts are important clinical entities because of their tendency to increase in size over time, potentially causing complications and eroding the surrounding bone tissue.
A technique called osteo-odonto-keratoprosthesis (OOKP) uses a staged operation on those who have developed corneal blindness in which a laminated tooth is transplanted to serve as a support for an artificial optical cylinder.
2,5-Diketopiperazine is an organic compound with the formula (NHCH2C(O))2. The compound features a six-membered ring containing two amide groups at opposite positions in the ring. It was first compound containing a peptide bond to be characterized by X-ray crystallography in 1938. It is the parent of a large class of 2,5-Diketopiperazines (2,5-DKPs) with the formula (NHCH2(R)C(O))2 (R = H, CH3, etc.). They are ubiquitous peptides in nature. They are often found in fermentation broths and yeast cultures as well as embedded in larger more complex architectures in a variety of natural products as well as several drugs. In addition, they are often produced as degradation products of polypeptides, especially in foods and beverages. They have also been found in extraterrestrial objects such as comets and asteroids.
Marcey Lynn Waters is the Glen H. Elder Jr., Distinguished Professor of Chemistry at the University of North Carolina, Chapel Hill (UNC-CH). She is an organic chemist whose research is at the interface of chemical biology and supramolecular chemistry. Waters has received multiple awards for research, teaching, and advocating for women in science. She served as president of the American Peptide Society (APS) from 2017 to 2019. Waters graduated from the University of California, San Diego with a degree in chemistry in 1992. While an undergraduate, she worked with Prof. Charles L. Perrin studying fundamental aspects of aromaticity. Waters entered the University of Chicago for her doctoral degree in chemistry, working with Prof. William D. Wulff studying the mechanism for the Wulff-Dotz benzannulation reaction between Fischer carbene complexes. and alkynes. Walters graduated from Chicago in 1997 with a PhD in chemistry. She was an NIH postdoctoral fellow in Prof. Ronald Breslow's group from 1997 to 1999, where she worked on dinuclear metalloenzyme mimics and antiaromaticity.
In normal usage, the rate-limiting step or rate-determining step is defined as the slowest step of a chemical reaction that determines the speed (rate) at which the overall reaction proceeds. The flux control coefficients do not measure this kind of rate-limiting. For example, in a linear chain of reactions at steady-state, all steps carry the same flux. That is, there is no slow or fast step with respect to the rate or speed of a reaction. The flux control coefficient, instead, measures how much influence a given step has on the steady-state flux. A step with a high flux control coefficient means that changing the activity of the step (by changing the expression level of the enzyme) will have a large effect on the steady-state flux through the pathway and vice versa. Historically the concept of the rate-limiting steps was also related to the notion of the master step. However, this drew much criticism due to a misunderstanding of the concept of the steady-state. Elasticity coefficient Metabolic control analysis Summation theorems (biochemistry)
Sources: en.wikipedia.org
Some studies have shown that principal antitubercular action of PAS occurs via poisoning of folate metabolism. Specifically, 4-aminosalicylic acid is incorporated into the folate pathway in place of the correct 4-aminobenzoic acid (PABA) by dihydropteroate synthase (DHPS) to generate hydroxyl-dihydropteroate (HO-H2Pte; 2'-hydroxy-7,8-dihydropteroate). This product is then used by dihydrofolate synthase (DHFS) to make a hydroxyl-dihydrofolate (HO-H2PteGlu) antimetabolite. HO-H2PteGlu competes with dihydrofolate for the binding site of dihydrofolate reductase (DHFR) and blocks the enzymatic activity.
== Precautions == Like other rare-earth metals, lutetium is regarded as having a low degree of toxicity, but its compounds should be handled with care nonetheless: for example, lutetium fluoride inhalation is dangerous and the compound irritates skin. Lutetium nitrate may be dangerous as it may explode and burn once heated. Lutetium oxide powder is toxic as well if inhaled or ingested. Similarly to the other rare-earth metals, lutetium has no known biological role, but it is found even in humans, concentrating in bones, and to a lesser extent in the liver and kidneys. Lutetium salts are known to occur together with other lanthanide salts in nature; the element is the least abundant in the human body of all lanthanides. Human diets have not been monitored for lutetium content, so it is not known how much the average human takes in, but estimations show the amount is only about several micrograms per year, all coming from tiny amounts absorbed by plants. Soluble lutetium salts are mildly toxic, but insoluble ones are not.
=== Legal status === In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kyinsu, intended for treatment of type 2 diabetes mellitus. The applicant for this medicinal product is Novo Nordisk A/S. Insulin icodec/semaglutide was authorized for medical use in the European Union in November 2025.
=== Insects === Order Blattodea Blattella germanica, German cockroach (2018) Periplaneta americana, American cockroach (2018) Zootermopsis nevadensis, a dampwood termite (2014 Cryptotermes secundus, a drywood termite(2018) Macrotermes natalensis, a higher termite (2014 Order Coleoptera Dendroctonus ponderosae Hopkins, beetle (mountain pine beetle) (2013) Aquatica lateralis, Japanese aquatic firefly "Heike-botaru" (firefly) (2018) Photinus pyralis, Big Dipper firefly (2018) Protaetia brevitarsis, White-spotted flower chafer (2019) Tribolium castaneum Strain:GA-2, beetle (red flour beetle) (2008) Allomyrina dichotoma, Japanese rhinoceros beetle (2022) Pachyrhynchus sulphureomaculatus, Easter Egg Weevil (2021) Order Collembola Family Isotomidae Desoria tigrina, (2021) Family Sminthurididae Sminthurides aquaticus, (2021) Order Diptera Family Calliphoridae Aldrichina grahami, Forensic blowfly (2020) Family Chironomidae Dasypogon diadema, Hunting Robber fly (2019) Parochlus steinend, Antarctic winged midge (2017) Proctacanthus coquilletti, Assassin fly (2017) Family Culicidae (mosquitoes) Aedes aegypti Strain:LVPib12, mosquito (vector of dengue fever, etc.) (2007) Aedes albopictus (2015) Anopheles darlingi Anopheles gambiae Strain: PEST, mosquito (vector of malaria) (2002) Anopheles gambiae Strain: M, mosquito (vector of malaria) (2010) Anopheles gambiae Strain: S, mosquito (vector of malaria) (2010) Anopheles sinensis, mosquito (vector of vivax malaria, lymphatic filariasis and Setaria infections), (2014) Anopheles stephensii Anopheles arabiensis (2015) Anopheles quadriannulatus (2015) Anopheles merus (2015) Anopheles melas (2015) Anopheles christyi (2015) Anopheles epiroticus (2015) Anopheles maculatus (2015) Anopheles culicifacies (2015) Anopheles minimus (2015) Anopheles funestus (2015, 2019) Anopheles dirus (2015) Anopheles farauti (2015) Anopheles atroparvus (2015) Anopheles sinensis (2015) Anopheles albimanus (2015) Culex quinquefasciatus, mosquito (vector of West Nile virus, filariasis etc.) (2010) Family Drosophilidae (fruit flies) Drosophila albomicans, fruit fly (2012) Drosophila ananassae, fruit fly (2007) Drosophila biarmipes, fruit fly (2011) Drosophila bipectinata, fruit fly (2011) Drosophila erecta, fruit fly (2007) Drosophila elegans, fruit fly (2011) Drosophila eugracilis, fruit fly (2011) Drosophila ficusphila, fruit fly (2011) Drosophila grimshawi, fruit fly (2007) Drosophila kikkawai, fruit fly (2011) Drosophila melanogaster, fruit fly (model organism) (2000) Drosophila mojavensis, fruit fly (2007) Drosophila neotestacea, fruit fly (transcriptome 2014) Drosophila persimilis, fruit fly (2007) Drosophila pseudoobscura, fruit fly (2005) Drosophila rhopaloa, fruit fly (2011) Drosophila santomea, fruit fly () Drosophila sechellia, fruit fly (2007) Drosophila simulans, fruit fly (2007) Drosophila takahashi, fruit fly (2011) Drosophila virilis, fruit fly (2007) Drosophila willistoni, fruit fly (2007) Drosophila yakuba, fruit fly (2007) Family Phoridae Megaselia abdita, scuttle fly (transcriptome 2013) Family Psychodidae (drain flies) Clogmia albipunctata, moth midge (transcriptome 2013) Family Sarcophagidae (flesh flies) Sarcophaga Bullata, Flesh fly (2019) Family Syrphidae (hoverflies) Episyrphus balteatus, hoverfly (transcriptome 2011) Order Hemiptera Acyrthosiphon pisum, aphid (pea aphid) (2010) Ericerus pela, Chinese wax scale insect (2019) Laodelphax striatellus, small brown planthopper (2017) Lycorma delicatula, spotted lanternfly (2019) Rhodnius prolixus, kissing-bug (2015) Rhopalosiphum maidis, Corn leaf aphid (2019) Sitobion miscanthi, Indian grain aphid (2019) Triatoma rubrofasciata, assassin bug (2019) Order Hymenoptera Acromyrmex echinatior colony Ae372, ant (Panamanian leafcutter) (2011) Apis mellifera, bee (honey bee), (model for eusocial behavior) (2006) Atta cephalotes, ant (leaf-cutter ant) (2011) Camponotus floridanus, ant (2010) Cerapachys biroi, ant (clonal raider ant)(2014) Euglossa dilemma, Green orchid bee (2017) Harpegnathos saltator, ant (2010) Lasius niger, ant (black garden ant)(2017) Linepithema humile, ant (Argentine ant) (2011) Nasonia giraulti, wasp (parasitoid wasp) (2010) Nasonia longicornis, wasp (parasitoid wasp) (2010) Nasonia vitripennis, wasp (parasitoid wasp; model organism) (2010) Netelia fuscicornis, wasp (parasitoid wasp) (2024) Nomia Melanderi, Alkali bee (2019) Pogonomyrmex barbatus, ant (red harvester ant) (2011) Solenopsis invicta, ant (fire ant) (2011) Order Lepidoptera Abrostola tripartita Hufnagel, Spectacle (2021) Achalarus lyciades, Hoary Edge Skipper (2017) Ahamus jianchuanensis, Jianchuan ghost moth (2024) Antharaea yamamai, Japanese oak silk moth (2019) Arctia plantaginis, Wood tiger moth (2020) Bicyclus anynana, squinting bush brown (2017) Bombyx mori Strain:p50T, moth (domestic silk worm) (2004) Calycopis cecrops, Red-Banded Groundstreak (2016) Calycopis isobeon, Dusky-Blue Groundstreak (2016) Coenonympha arcania, Pearly Heath (2024) Cydia pomonella, codling moth (2019) Danaus plexippus, monarch butterfly) (2011) Erebia cassioides, Common Brassy Ringlet (2025) Heliconius melpomene, butterfly (2012) Keiferia lycopersicella, Tomato pinworm (2024) Melitaea cinxia, Glanville fritillary butterfly (2014) Megathymus ursus violae, bear giant skipper butterfly (2018) Morpho helenor, Common blue morpho (2023) Morpho achilles, Blue-banded morpho (2023) Morpho deidamia (2023) Papilio bianor, Chinese peacock butterfly (2019) Phthorimaea absoluta, Tomato leafminer (2024) Pieris rapae, small cabbage white butterfly (2016) Plodia interpunctella, Indianmeal moth (2022) Plutella xylostella, moth (diamondback moth) (2013) Scrobipalpa atriplicella, Goosefoot groundling moth (2024) Spodoptera frugiperda, Fall armyworm (2017) Thitarodes armoricanus, Himalaya ghost moth (2024) Thitarodes xiaojinensis, Xiaojin ghost moth (2024) Troides aeacus, Golden birdwing (2024) Eudocima phalonia, fruit-piercing moth (2017) Order Orthoptera Locusta migratoria, migratory locust (2014) Schistocerca gregaria, desert locust (2020) Gryllus bimaculatus, two-spotted cricket (2021) Order Phthiraptera Pediculus humanus, louse (sucking louse; parasite) (2010) Menopon gallinae, Poutlry shaft louse (2024) Psocoptera Liposcelis brunnea, booklouse (2022) Order Raphidioptera Venustoraphidia nigricollis, black-necked snakefly (2023) Order Trichoptera Eubasilissa regina, purple caddisfly (2022,) Stenopsyche tienmushanensisi, Caddisfly (2018) Order Mantodea Tenodera sinensis, chinese praying mantis (2023)
==== Shoulder disorders ==== A 2014 Cochrane review found insufficient evidence to determine whether electrotherapy was better than exercise at treating adhesive capsulitis. As of 2004, there is insufficient evidence to draw conclusions about any intervention for rotator cuff pathology, including electrotherapy; furthermore, methodological problems precluded drawing conclusions about the efficacy of any rehabilitation method for impingement syndrome.
Sources: en.wikipedia.org
Leslie Harold Collier (9 February 1921 – 14 March 2011) was a scientist responsible for developing a freeze-drying method to produce a more heat stable smallpox vaccine in the late 1940s. Collier added a key component, peptone, a soluble protein, to the process. This protected the virus, enabling the production of a heat-stable vaccine in powdered form. Previously, smallpox vaccines would become ineffective after 1–2 days at ambient temperature. The development of his vaccine production method played a large role in enabling the World Health Organization to initiate its global smallpox eradication campaign in 1967.
While the Cro-Magnons are usually assumed to have generally practised sexual division of labour with men hunting and women gathering such as in the preponderance of recent hunter-gatherer societies, it is unclear to what extent this may be applied to Neanderthals. Both Neanderthal men and women have similar traumatic injury patterns, which might imply that both sexes were involved in hunting. Dental wearing patterns among Neanderthals, on the other hand, could indicate men and women typically carried different items with their mouths, though these may not have been related to subsistence tasks. The women at El Sidrón Cave, Spain, may have been eating more seeds and nuts than the men. The lack of distinctive task specialization in Neanderthals has usually been linked to their small population and group size, falling short of the demographic threshold where task specialization becomes feasible — which may also explain the comparative simplicity of Neanderthal material culture.
The timing of the Kosvinsky facilities completion date is regarded as one explanation for U.S. interest in a new nuclear "bunker buster" Earth-penetrating warhead and the declaration of the deployment of the B-61 mod 11 in 1997; Kosvinsky is protected by about 1000 feet of granite.
Kopeček, "Super-Resolution Imaging and Quantitative Analysis of Membrane Protein/Lipid Raft Clustering Mediated by Cell Surface Self-Assembly of Hybrid Nanoconjugates". ChemBioChem 16, 1725–1729 (2015) R. Zhang, J. Yang, M. Sima, Y. Zhou, J. Kopeček, "Sequential Combination Therapy of Ovarian Cancer with Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Paclitaxel and Gemcitabine Conjugates". Proceedings of the National Academy of Sciences of the United States of America 111(33), 12181–12186 (2014) T.-W. Chu, J. Yang, J. Kopeček, "Anti-CD20 Multivalent HPMA Copolymer-Fab’ Conjugates for the Direct Induction of Apoptosis". Biomaterials 33, 7174–7181 (2012) H. Pan, J. Yang, P. Kopečková, J. Kopeček. :Backbone Degradable Multiblock N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates via Reversible Addition-Fragmentation Chain Transfer Polymerization and Thiol-ene Coupling Reaction". Biomacromolecules 12, 247–252 (2011) K. Wu, J. Liu, R.N. Johnson, J. Yang, J. Kopeček, "Drug-Free Macromolecular Therapeutics: Induction of Apoptosis by Coiled-Coil Mediated Crosslinking of Antigens on Cell Surface". Angewandte Chemie International Edition 49, 1451–1455 (2010) J. Kopeček, P. Kopečková, "HPMA Copolymers: Origins, Early Developments, Present, and Future". Advanced Drug Delivery Reviews 62, 122–149 (2010) J. Kopeček, "Hydrogels. From Soft Contact Lenses and Implants to Self-Assembled Nanomaterials". Journal of Polymer Science Part A: Polymer Chemistry 47, 5929–5946 (2009) J. Yang, C. Xu, C. Wang, J.
=== Pharmacokinetics === The elimination half-lives of clinically used orexin receptor antagonists are 12 hours for suvorexant, about 17 to 19 hours ("effective" half-life) or 55 hours (terminal elimination half-life) for lemborexant, and 6 to 10 hours for daridorexant. The elimination half-lives of investigational orexin receptor antagonists are 2 to 3 hours for seltorexant and about 1.5 to 3 hours for vornorexant. The pharmacokinetics of suvorexant are significantly affected by age, sex, and other factors, leading to increased blood concentrations in female, obese, and older patients. These factors do not significantly affect the pharmacokinetics of lemborexant or daridorexant. All three marketed orexin antagonists do not need to be dose adjusted in patients with reduced renal function, as the pharmacokinetic profiles of these medications are not significantly affected. In patients with moderate to severe hepatic impairment, dose adjustments of these medications may be necessary.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.